A structured approach to gastrointestinal adverse effect management during xanomeline-trospium treatment for schizophrenia
Psychiatry Research Case Reports · 2026-11 · 100355
DOI: 10.1016/j.psycr.2026.100355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry Research Case Reports, 2026-11. Verfasst von Monique Booher und 1 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Xanomeline-trospium is the first approved muscarinic receptor agonist-based treatment for schizophrenia and represents an alternative to dopamine D2 receptor antagonism. Across the EMERGENT clinical trials, gastrointestinal adverse effects, including nausea, vomiting, constipation, and dyspepsia, were among the most frequently reported treatment-emergent adverse events. This report describes a patient with schizophrenia who developed clinically significant gastrointestinal intolerance during early xanomeline-trospium treatment. Constipation and nausea developed during the first two weeks of treatment, with subsequent vomiting and abdominal pain prompting emergency department evaluation and temporary treatment interruption. After improvement in symptoms, xanomeline-trospium was successfully restarted at a reduced dose and continued without recurrence of the severe gastrointestinal symptoms that prompted emergency evaluation. This case illustrates an evolving and overlapping gastrointestinal symptom burden during xanomeline-trospium treatment and highlights temporary interruption followed by reduced-dose rechallenge as a potential management strategy when clinically significant gastrointestinal intolerance occurs.
Zitieren
APA
Booher, M., & Burky, G. (2026). A structured approach to gastrointestinal adverse effect management during xanomeline-trospium treatment for schizophrenia. Psychiatry Research Case Reports, 100355. https://doi.org/10.1016/j.psycr.2026.100355
Vancouver
Booher M, Burky G. A structured approach to gastrointestinal adverse effect management during xanomeline-trospium treatment for schizophrenia. Psychiatry Research Case Reports. 2026:100355. doi:10.1016/j.psycr.2026.100355
BibTeX
@article{Booher2026,
author = {Booher, Monique and Burky, Garrison},
title = {A structured approach to gastrointestinal adverse effect management during xanomeline-trospium treatment for schizophrenia},
journal = {Psychiatry Research Case Reports},
year = {2026},
pages = {100355},
doi = {10.1016/j.psycr.2026.100355}
}
EUVIMED